Intervention Protocol

Combination chemotherapy versus single agent chemotherapy during preoperative chemoradiation for resectable rectal cancer

  1. Heloisa M Resende1,*,
  2. Suzana Angelica Silva Lustosa2,
  3. Vinícius Menandro3,
  4. Juliana Novaes3,
  5. Delcio Matos4

Editorial Group: Cochrane Colorectal Cancer Group

Published Online: 16 JUN 2010

Assessed as up-to-date: 22 MAR 2010

DOI: 10.1002/14651858.CD008531


How to Cite

Resende HM, Lustosa SAS, Menandro V, Novaes J, Matos D. Combination chemotherapy versus single agent chemotherapy during preoperative chemoradiation for resectable rectal cancer (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD008531. DOI: 10.1002/14651858.CD008531.

Author Information

  1. 1

    UNIFESP - Escola Paulista de Medicina, Gastroenterological Surgery, Volta Redonda, Rio de Janeiro, Brazil

  2. 2

    Hospital Municipal Dr. Munir Rafful, Extension, Research, Teaching Unit - UEPE, Volta Redonda, RJ, Sao Paolo, Brazil

  3. 3

    Centro Universitário de Volta Redonda, Medicine School, Volta Redonda, Rio de Janeiro, Brazil

  4. 4

    UNIFESP - Escola Paulista de Medicina, Gastroenterological Surgery, São Paulo, São Paulo, Brazil

*Heloisa M Resende, Gastroenterological Surgery, UNIFESP - Escola Paulista de Medicina, Rua Juiz Nitho Leite 45 apto 301-Jardim Primavera, Volta Redonda, Rio de Janeiro, 27283-430, Brazil. heloisa.resende@terra.com.br.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 16 JUN 2010

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To compare patients outcomes (including overall survival, disease free survival and toxicity) between two chemotherapy schedules in stage II and III rectal cancer given as part of pre-operative chemoradiation. The control comparison will be radiotherapy and a fluoropyrimidine, and the intervention will be radiotherapy, fluoropyrimidine and an additional drug(s), excluding biological agents.